CLINICAL STUDY:
Prescriptive Patient Extracorporeal Circuit and Oxygenator Sizing Reduces Hemodilution and Allogeneic Blood Product Transfusion during Adult Cardiac Surgery. JECT. 2013; 45:167-172. Bronson S, et al. (PDF)
|
ABSTRACT:
Beneficial Effects of Modern Perfusion Concepts in Aortic Valve and Aortic Root Surgery. Perfusion 2009;24: 37-44, Kutschka, et al.
In this 170-patient study, the use of the ROCSafe Hybrid Perfusion System was found to reduce side effects of standard extracorporeal circulation.
|
ABSTRACT:
Blood Separation with Two Different Autotransfusion Devices: Effects on Blood Cell Quality and Coagulation Variables. Int. J Artif Organs, Dec 1998; 2: 820-4. Rosalski, et al.
The authors compare the Fresenius C.A.T.S System with another device and found that C.A.T.S had a higher platelet recovery rate and higher platelet concentration.
|
ABSTRACT:
Investigation of Blood Compatibility of PMEA-Coated Extracorporeal Circuits. Journal of Bioactive and Compatible Polymers, Vol 17, Sept 2002. Kocakulak M, et al.
In a study comparing PMEA-coated and uncoated oxygenators, the authors found greater retention of clotting factors and platelets and less post-op hemorrhaging when using PMEA-coated oxygenators.
|
ABSTRACT:
Emerging Technologies in Biocompatible Surface Modifying Additives: Quest for Physiologic CPB. Cardiovascular and Hematological Agents. 2004; Vol. 2:No 4. Gunaydin S, et al.
The authors compare surface coatings, including Xcoating, in 155 CPB cases for chemical composition, biomaterial evaluation and clinical efficacy.
|
ABSTRACT:
Biocompatibility of Poly (2-methoxyethylacrylate) Coating for Cardiopulmonary Bypass. Annals Thoracic Cardiovascular Surgery, 2003, Volume 9, No 1. Noguchi, et al.
The authors compare the biocompatibility of PMEA-coated and heparin-coated circuits by measuring several inflammatory markers. Results indicate PMEA-coated circuits are as biocompatible as heparin coated circuits.
|
ABSTRACT:
Xcoating: A New Biopassive Polymer Coating. Canadian Perfusion Canadienne, Volume 11, No 2, June 2001. Schiel, et al.
This paper explains the mechanism and benefits of Xcoating.
|
ABSTRACT:
Non-Pharmacologic Therapeutic Strategies for Reducing Complications of Cardiopulmonary Bypass. Filtration 2005; 1(2):95-106. Gunaydin S, et al.
This study of 225 patients undergoing CPB concludes that the use of circuits with leukocyte filtration and Xcoating provides clinically significant benefits for high risk patients.
|
ABSTRACT:
Intraoperative Autotransfusion in Small Children: An In-vitro Investigation to Study its Feasibility. Anesth Analg, April 1999; 88(4): 763-6. Booke, et al.
This in-vitro study demonstrates the ability of the Fresenius C.A.T.S System to produce high quality HCT independent of blood volume suggesting the feasibility of IAT in small children.
|
ABSTRACT:
Quality of Processed Blood for Autotransfusion. JECT March 2000; 32: 11-9. Shulman, et al.
The authors evaluate the quality of processed blood using several parameters and demonstrate that the C.A.T.S System has a high washout efficiency and produces consistently high HCT at high flow rates.
|